Codexis (CDXS) Stock Jumps 2.4% Following Strong Q4 Earnings Report

TLDR

• Codexis (CDXS) exceeded Q4 EPS projections by $0.10, posting $0.11 compared to analyst expectations of $0.01
• Fourth-quarter revenue reached $38.9 million, an 81% increase from the previous year, surpassing the $35.83 million forecast
• Q4 performance was boosted by a $37.8 million Technology Transfer Agreement with Merck
• Annual net loss for 2025 improved to $44.0 million from $65.3 million in the prior year
• Management projects 2026 revenue between $72 million and $76 million; sufficient cash reserves through 2027

On March 11, 2026, Codexis delivered its fourth-quarter and full-year 2025 financial results, surpassing analyst projections across key metrics. Shares responded positively, gaining 2.4% to reach $1.27.

The company posted Q4 earnings per share of $0.11, exceeding consensus forecasts by $0.10. Quarterly revenue totaled $38.9 million, outperforming the $35.83 million projection and representing an 81% year-over-year increase from the $21.5 million recorded in Q4 2024.

The substantial revenue growth stemmed primarily from a Technology Transfer Agreement with Merck worth $37.8 million, which was finalized during the fourth quarter and significantly impacted overall results.

Codexis, Inc., CDXS

Looking at the full-year performance, total revenue increased 19% to $70.4 million compared to $59.3 million in 2024. Product gross margin showed meaningful improvement, expanding to 64% from the previous year’s 56%.

The company’s annual net loss contracted significantly to $44.0 million ($0.50 per share) from the 2024 loss of $65.3 million ($0.89 per share). Notably, Q4 generated positive net income of $9.6 million, a stark contrast to the $10.4 million loss recorded in the same quarter last year.

Selling, general and administrative expenses decreased to $47.1 million annually, down from $55.1 million in 2024, primarily due to reductions in stock-based compensation and legal costs. Research and development investment increased to $52.3 million from $46.3 million.

The company also recorded $3.4 million in restructuring charges during the year, associated with a workforce reduction implemented in November 2025.

Cash Position and Guidance

Codexis closed 2025 with $78.2 million in cash, cash equivalents and short-term investments. Management indicated this financial cushion provides adequate runway through the conclusion of 2027.

For the upcoming year, the company projects total revenues ranging from $72 million to $76 million.

Regarding business development, Codexis reported active engagement with more than 40 companies spanning 55 potential opportunities. CEO Alison Moore highlighted that discussions have evolved beyond initial feasibility testing toward comprehensive contract negotiations.

The company has secured a lease for a GMP facility with kilogram-scale manufacturing capabilities. Retrofit construction is scheduled to commence in the latter half of 2026, with full operational capacity anticipated by year-end 2027.

Codexis has also established an agreement with Axolabs—marking its third CDMO partnership—to assess its ECO Synthesis technology at Axolabs’ production facility.

Analyst Sentiment and Institutional Activity

Notwithstanding the positive earnings results, analyst outlook remains cautious. Weiss Ratings maintained a “Sell” recommendation on January 21, and the MarketBeat consensus also indicates “Sell.”

Shares currently trade nearer to the 52-week low of $0.96 than the high of $3.87, with a market capitalization of $114.7 million. The 50-day moving average stands at $1.39, while the 200-day average is $1.90.

Institutional investors have demonstrated increased interest. Millennium Management expanded its position by 3,376.5% during Q3. Renaissance Technologies increased its holdings by 137.5% in Q4. Institutional ownership currently represents 78.54% of outstanding shares.

The company aims to secure a licensing agreement with a major pharmaceutical company during the second half of 2026 and intends to share stereoisomer control data at the 2026 TIDES USA annual meeting.

The post Codexis (CDXS) Stock Jumps 2.4% Following Strong Q4 Earnings Report appeared first on Blockonomi.